The identification of epidermal growth factor receptor (EGFR) mutations in NSCLC and the association between EGFR mutations and gefitinib sensitivity have changed the way lung cancer is diagnosed and treated [2]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.